---
title: "Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: PDE4 inhibitors"
description: "Formulary evidence on Envudeucitinib (ESK-001, FTP-637) in Moderate-to-severe plaque psoriasis: PDE4 inhibitors. Topics: FDA-approved indication, dosage, and titration: apremilast; Week 16 clinical response in Trials PSOR-1 and PSOR-2: apremilast label; ESTEEM 1: PASI-75 at week 16, maintenance through week 52, and adverse events; ESTEEM 2: PASI 75, PASI 50, and sPGA 0 or 1 at week 16 and common adverse events; 6 further topics. 10 evidence topics quoted from 6 sources."
canonical: "https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/product-information-and-disease-description/pde4-inhibitors"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: PDE4 inhibitors

<a id="heading-2.2.2.1.4"></a>

## 2.2.2.1.4 PDE4 Inhibitors

<a id="topic-2.2.2.1.4-1"></a>

### FDA-approved indication, dosage, and titration: apremilast

> “OTEZLA/OTEZLA XR is indicated for the treatment of adult patients with plaque psoriasis who are candidates for phototherapy or systemic therapy.”
> “Following the 5-day titration with OTEZLA, the recommended maintenance dosage is OTEZLA 30 mg twice daily or OTEZLA XR 75 mg once daily taken orally starting on Day 6.”
> “This titration is intended to reduce the gastrointestinal symptoms associated with initial therapy.”

Source: [Amgen OTEZLA prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/205437s016lbl.pdf)

<a id="topic-2.2.2.1.4-2"></a>

### Week 16 clinical response in Trials PSOR-1 and PSOR-2: apremilast label

| Endpoint at Week 16, n (%) | PSOR-1 placebo (N = 282) | PSOR-1 OTEZLA 30 mg BID (N = 562) | PSOR-2 placebo (N = 137) | PSOR-2 OTEZLA 30 mg BID (N = 274) |
| --- | --- | --- | --- | --- |
| PASI-75 | “15 (5.3)” | “186 (33.1)” | “8 (5.8)” | “79 (28.8)” |
| sPGA of clear or almost clear | “11 (3.9)” | “122 (21.7)” | “6 (4.4)” | “56 (20.4)” |

Source: [Amgen OTEZLA prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/205437s016lbl.pdf)

<a id="topic-2.2.2.1.4-3"></a>

### ESTEEM 1: PASI-75 at week 16, maintenance through week 52, and adverse events

> “ESTEEM 1 evaluated efficacy/safety of apremilast at 30 mg twice a day for moderate to severe plaque psoriasis.”
> “In all, 844 patients were randomized (n = 282, placebo; n = 562, apremilast).”
> “At week 16, significantly more patients taking apremilast achieved 75% or greater reduction from baseline Psoriasis Area and Severity Index score (PASI-75) (33.1%) versus placebo (5.3%, P < .0001; primary end point).”
> “Most (61.0%) patients rerandomized to apremilast at week 32 achieved PASI-75 at week 52 versus 11.7% rerandomized to placebo.”
> “During the placebo-controlled period, 55.7% and 69.3% of patients randomized to placebo and apremilast, respectively, had 1 or more adverse events.”

Source: [Papp et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/26089047/)

<a id="topic-2.2.2.1.4-4"></a>

### ESTEEM 2: PASI 75, PASI 50, and sPGA 0 or 1 at week 16 and common adverse events

> “ESTEEM 2 evaluated the efficacy and safety of apremilast 30 mg twice daily for moderate-to-severe plaque psoriasis.”
> “The modified intention-to-treat population (full analysis set) included 137 placebo and 274 apremilast patients.”
> “At week 16, significantly more apremilast patients achieved PASI 75 (28·8%), PASI 50 (55·5%) and static Physician's Global Assessment score of 0 or 1 (20·4%) vs. placebo (5·8%, 19·7%, 4·4%, respectively; P < 0·001).”
> “The most common adverse events were nausea, diarrhoea, nasopharyngitis and upper respiratory tract infection.”

Source: [Paul et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/26357944/)

<a id="topic-2.2.2.1.4-5"></a>

### Adverse reactions through week 16 in adults with moderate to severe plaque psoriasis: apremilast label

| Adverse reaction, n (%) | Placebo (N = 506) | OTEZLA 30 mg BID (N = 920) |
| --- | --- | --- |
| Diarrhea | “32 (6)” | “160 (17)” |
| Nausea | “35 (7)” | “155 (17)” |
| Tension headache | “21 (4)” | “75 (8)” |
| Headache | “19 (4)” | “55 (6)” |

Source: [Amgen OTEZLA prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/205437s016lbl.pdf)

<a id="topic-2.2.2.1.4-6"></a>

### Discontinuation, depression, and weight decrease: apremilast label

> “The proportion of subjects with plaque psoriasis who discontinued treatment due to any adverse reaction was 6.1% for subjects treated with OTEZLA 30 mg twice daily and 4.1% for placebo-treated subjects.”
> “Treatment with apremilast is associated with an increased incidence of depression.”
> “During the 16-week placebo-controlled period of the 3 controlled clinical trials in adult subjects with moderate to severe plaque psoriasis, 1.3% (12/920) of subjects treated with OTEZLA reported depression compared to 0.4% (2/506) treated with placebo.”
> “During the placebo-controlled period of the trials in adults with moderate to severe plaque psoriasis, weight decrease between 5%-10% of body weight occurred in 12% (96/784) of subjects treated with OTEZLA compared to 5% (19/382) treated with placebo.”

Source: [Amgen OTEZLA prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/205437s016lbl.pdf)

<a id="topic-2.2.2.1.4-7"></a>

### Apremilast: guideline recommendation, gastrointestinal adverse effects, and absence of laboratory monitoring

> “Apremilast is recommended for the treatment of moderate to severe psoriasis in adults.”
> “In those experiencing GI adverse effects, 70% to 80% occurred within the first 2 weeks, 75% to 80% were mild in severity, and 60% to 65% resolved within the first month.”
> “These benefits include oral administration and the lack of a requirement for laboratory monitoring.”
> “For patients who would prefer to avoid frequent injections as well as laboratory monitoring and are willing to accept a slower onset of skin clearance and lower likelihood of clearing, apremilast is an appropriate choice.”

Source: [Menter et al. (2020)](https://www.jaad.org/article/S0190-9622%2820%2930284-X/fulltext)

<a id="topic-2.2.2.1.4-8"></a>

### Network meta-analysis: phosphodiesterase-4 inhibitors, serious adverse events and PASI 75 compared with biologics

> “Phosphodiesterase‐4 inhibitors had the highest SUCRA at class level in terms of SAEs (versus placebo: RR 0.76, 95% CI 0.47 to 1.23; SUCRA = 70.8)”
> “There was evidence of a difference in favour of infliximab, anti‐IL17 agents (ixekizumab, bimekizumab, and secukinumab), and risankizumab compared to ustekinumab, other anti‐TNF‐alpha agents (adalimumab, certolizumab, and etanercept), and synthetic targeted treatments (apremilast and deucravacitinib) in terms of achieving PASI 75.”

Source: [Sbidian et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12327466/)

<a id="topic-2.2.2.1.4-9"></a>

### Network meta-analysis: estimated PASI response rates at 10 to 16 weeks for apremilast and dimethyl fumarate

| Treatment | PASI 75, % (95% CrI) | PASI 90, % (95% CrI) | PASI 100, % (95% CrI) |
| --- | --- | --- | --- |
| Apremilast, 30 mg | “30.8 (26.8-35.0)” | “12.1 (9.9-14.7)” | “2.4 (1.8-3.1)” |
| Dimethyl fumarate | “29.6 (22.0-38.3)” | “11.4 (7.5-16.7)” | “2.2 (1.2-3.8)” |
| Placebo | “5.3 (4.8-5.9)” | “1.1 (1.0-1.3)” | “0.1 (0.1-0.1)” |

Source: [Armstrong et al. (2020a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7042876/)

<a id="topic-2.2.2.1.4-10"></a>

### Network meta-analysis design: bayesian analysis of short-term PASI response at 10 to 16 weeks in 60 trials and a traditional meta-analysis at 44 to 60 weeks

> “A bayesian network meta-analysis was conducted to estimate short-term PASI response rates; to account for variation across trials, an ordinal model that adjusted for reference arm response was implemented.”
> “The long-term PASI rates were estimated via a traditional meta-analysis.”
> “In a network meta-analysis of 60 clinical trials for short-term efficacy, brodalumab, guselkumab, ixekizumab, and risankizumab-rzaa had the highest Psoriasis Area and Severity Index response rates at 10 to 16 weeks from baseline.”
> “A total of 60 trials meeting all inclusion criteria were included in the base-case NMA.”
> “The base-case analysis included all biologics, apremilast, and dimethyl fumarate.”
> “The estimated PASI response rates were summarized using posterior medians and their associated 95% credible intervals (CrIs).”

Source: [Armstrong et al. (2020a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7042876/)

## Related pages
- [Envudeucitinib (ESK-001): Moderate-to-severe plaque psoriasis](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Terms and abbreviations](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/terms-and-abbreviations.md)
- [Envudeucitinib (ESK-001): Moderate-to-severe plaque psoriasis](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/executive-summary.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Product information and disease description](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/product-information-and-disease-description.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Clinical evidence](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/clinical-evidence.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Economic information and modeling report](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/economics) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/economics.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: References](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/references) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/references.md)
